CJC-1295 (no DAC)
Also called Mod GRF 1-29
What to know about CJC-1295 (no DAC)
The product called CJC-1295 without DAC is generally a short-acting modified GHRH(1-29) analogue. It is chemically and pharmacokinetically distinct from long-acting CJC-1295 DAC.
- How it may work
- It is intended to stimulate pituitary GHRH receptors and preserve pulsatile growth-hormone release. Removing the albumin-binding DAC group shortens exposure.
- What research found
- Human GHRH(1-29) studies demonstrate acute growth-hormone responses, but published CJC-1295 trials studied the DAC-linked compound. Results from the long-acting form should not be transferred directly.
- What is not settled
- Human product-specific data are sparse. Endocrine, glucose, fluid-balance, and product-quality risks are not well quantified.
- Research and product status
- CJC-1295 without DAC has no licensed U.S. product. Naming is inconsistent across sellers, making exact sequence verification important.
Research reference
- Research amount range
- 100–300 mcg per administration — not a starting amount
- Reference frequency
- Every day — catalogue input, not a personal schedule
- Evidence route
- No human administration route established by this catalogue's evidence tier.
- Model accumulation timescale
- ~3 hours — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
- When change was measured
- Evidence commonly used for no-DAC CJC-1295 comes from acute GHRH(1-29) hormone-response experiments. Those minutes-to-hours biomarker findings do not establish a body-composition or recovery timeline.
- When to assess
- No direct long-duration human outcome trial provides a reassessment week for this specific no-DAC material. Data from long-acting DAC conjugates should not be transferred to it.
- Conditions and limitations
- No controlled outcome study establishes that fasting, bedtime timing, or pairing with a secretagogue is required. Those conventions are not the same as demonstrated outcome conditions.
- When to stop
- No validated course length, target, maintenance phase, or quit rule exists. Lack of an early subjective effect is not a basis for increasing frequency or extending exposure.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Combination evidence and cautions
What is known and unknown about CJC-1295 (no DAC) alongside other compounds or medicines.
Key properties
- Formula
- C152H252N44O42
- Mol. weight
- 3,367.97 Da
- PubChem CID
- 91976842
External references
The modified GRF(1-29) sold without DAC has no human trial of its own — sermorelin and the DAC conjugate are different molecules — so no schedule table is shown.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 3hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- GHRH + GHRP synergy literatureGHRH analogs amplify GHRP-driven GH pulses when co-timed.